The Latest Breaking News from AstraZeneca

This biotech stock is a promising buy, but it does come with risks.

Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery

AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression outcomes in treated patients.

AstraZeneca appoints Iskra Reic as new head of China operations amid investigations and challenges in the pharmaceutical industry in China.

Every 30 seconds, someone in the world will experience a flare-up of their asthma or chronic obstructive pulmonary disease (COPD) symptoms. For decades, the standard treatment for these potentially life-threatening episodes has remained unchanged – treatment with steroids, such as prednisolone.

Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines.

Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca's Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically

National Institute for Health and Care Excellence unable to reach price agreement with manufacturers of Enhertu

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name Enhertu.